



## **Symic to Present at the 13<sup>th</sup> Annual BIO Asia International Conference**

**SAN FRANCISCO, Mar. 10, 2016** – Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 13th Annual BIO Asia International Conference in Tokyo.

Conference details are as follows:

Date: Tuesday, Mar. 15, 2016

Time: 10:00 a.m. JST

Location: Grand Hyatt Tokyo, Japan, Drawing Room, 2nd Floor

### **About Symic**

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic's lead compound, SB-030, is currently under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury. In addition, Symic's osteoarthritis drug candidate, SB-061, is poised to enter the clinic in the next few months.

Symic is based in San Francisco. For additional information, please visit the company's website at <http://www.symic.bio> or follow us on Twitter at [www.twitter.com/symicbio](http://www.twitter.com/symicbio) and LinkedIn at [www.linkedin.com/company/symic-bio/](http://www.linkedin.com/company/symic-bio/).

###

### **Media Contacts**

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[lena.evans@russopartnersllc.com](mailto:lena.evans@russopartnersllc.com)